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WILSON'S disease is a rare genetic condition associated with excess copper
deposition in the tissues, principally liver and brain. It first became established as a
clinical entity in 1912, following Kinnear Wilson's publication of thirteen cases.'
The incidence has been estimated to be about one case per million ofthepopulation2
although Walshe3 considers it is likely to be more common than this. Since it is a
condition which can be effectively treated, early diagnosis is essential.3 4
In the space of six months, two cases with contrasting features have presented to
the Department of Neurology.
CASE 1 AG AGED 17 MALE
In 1979this patient, one ofidenticaltwinbrothers, joined the army, but dislikedit
and left after serving only threemonths. Hethen worked in abutcher's shopbut left
six months later, at the end of 1979, when he lost interest in this too. His family
noticed that he had become less sociable and he slept a great deal. Bythe summer of
1980 he had developed a peculiar nodding action of his head and he had become so
withdrawn that medical help was sought. A possible diagnosis ofschizophrenia was
considered and he was admitted for psychiatric care.
Over the next four months, he remained withdrawn and he developed slurred
speech and unsteadiness of walking. From December, 1980 to March, 1981 his
condition deteriorated rapidly with severe difficulty speaking and swallowing, and
increasing limb stiffness. By this time he was unable to walk and could not feed
himself.
On admission to the Neurology Unit hehad atotally immobile face, was unable to
speak and had great difficulty in swallowing. There were no involuntary
movements, but the limbs showed a severe degree of rigidity.
On examination ofthe eyes characteristic Kayser-Fleischer rings were found and a
confident diagnosis of Wilson's disease was made. This was confirmed by the
biochemical findings of low serum copper, low serum caeruloplasmin and raised
urinary copper clearance (Table 1). Liver function tests were normal apart from a
marginally elevated alkaline phosphatase to 149 u/l (normal 35-105). Liver biopsy
showed a marked increase in fibrous tissue and some nodular degeneration. The
copper content of this tissue was not estimated.
The family tree is shown in Fig. 1. A feature of particular interest is the
occurrence of this condition in one of identical twins. Confirmation of identical
genotypes was obtained by a detailed comparison of blood groups (Table 2). The
brother showed no clinical evidence of the disease. His biochemical findings (II4)
and those of the rest ofthe family are shown in Table 1.
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TABLE 1. BIOCHEMICAL PARAMETERS FOR FAMILY OF CASE 1.
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Fig 2 Effect on urinary copper clearance by
penicillamine in Case 1
Treatment was commenced with
d-penicillamine, 2 grams daily. Fig. 2
shows the increased clearance of copper
following treatment. Clinical response has
been disappointing. During the first three
months of treatment there was some
improvement in swallowing and after 18
months he is able to walk with help.
However, he remains severely disabled
and still unable to speak.
CASE 2 BM AGED 24 FEMALE
This young woman, who works
asaclerk, presented withahistory
of unsteadiness on her feet and
frequent falls, overa period ofsix
months. The unsteadiness had
become gradually worse and she
had also experienced difficulty
with writing, and drinking from a
cup, because of shaking hands.
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TABLF 2. COMPARISON OF BLOOD GROUPS IN TWINS
On examination, she was euphoric and had a variable coarse tremor ofthe upper
limbs at rest. It was made worse byvoluntary movement andtended tobecome quite
violent at times of excitement. She is right handed and this side was more severely
affected. Tone was normal and there was no weakness. Her gait was ataxic and at
times this became so severe that she almost fell. There was no nystagmus.
Initially adiagnosis ofmultiple sclerosis was considered likely, but examination of
the eyes again showed the diagnostic Kayser-Fiescher rings of Wilson's disease.
Biochemical screening confirmed the abnormal copper metabolism. She has three
siblings, none are affected clinically.
Treatment was started with d-penicillamine 2 grams daily. There was a good
biochemical response (Fig. 3) and clinically her condition also improved. However,
following discharge from hospital compliance was poor despite reduction ofdosage
to 500 mg daily. She developed nausea and a skin rash, and had one episode of
jaundice, probably haemolytic type (this occurred while she was at home and
confirmatory tests were not obtained).
Her clinical condition had deteriorated markedly by the end of 1981 and a further
attempt was made to achieve atherapeutic dose ofpenicillamineusing steroid cover.
Unfortunately side effects, particularly nausea proved again troublesome and the
drug had to be abandoned.
In February, 1982 triethylene tetramine dihydrochloride (Trien) was introduced
at a dose of600 mg daily increasing to 1500 mg daily and this has been successful in
maintaining a good urinary copper clearance (Fig. 3) with good tolerance. Her
clinical condition also improved as shown by her writing and drawing.
Unfortunately this patient's compliance with drug therapy has again been suspect
and the case continues to cause problems in management.
DISCUSSION
These two cases clearly demonstrate the variety of clinical manifestations of
neurological Wilson's disease and the difficulty which the diagnosis may present.
The importance of the diagnostic sign of Kayser-Fleischer rings cannot be over
emphasised and these should be carefully looked for by slit lamp examination if
necessary, in any unusual neurological syndrome in young people. Wilson's concept
ofprogressive lenticular degeneration is now recognised as too narrow since copper
is deposited throughout the brain including the cerebellum and cerebral cortex, and
notjust in the basal ganglia.' Damage can occur at any ofthese sites and give rise to
a variety of clinical manifestations. Walshe3 stresses this point and lists the
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Fig 3 Effects on urinary copper clearance by penicillamine and then
triethylene tetramine in treatment of Case 2
following features which have been documented in neurological Wilson's disease;
tremor, which may be of the Parkinsonian or intention variety, ataxia, rigidity,
drooling, dysphagia, behaviour disorders, in particular euphoria and intellectual
impairment, and seizures are also occasionally seen. A useful maxim is that no two
cases ofneurological Wilson's disease are entirely alike.
In retrospect our first case most closely fitted theclassicaltextbook description of
an extra pyramidal, Parkinsonian-like syndrome, but initially it was thebehavioural
disorder rather than anyphysical problem which caused diagnostic confusion. Inthe
second case the presenting features were largely those of a cerebellar disorder.
The ages of our two patients were 17 and 24 years, consistent with Walshe's3
average age of presentation in his series as 18.9 (range 5-40). Cases with a
predominantly hepatic presentation tend to be younger (average age 11.4 years).
Since the disease is inherited as an autosomal recessive trait, it is imperative to
screen siblings for early clinical features and biochemical abnormalities, a point
dramatically illustrated in Case 1, where an identical twin was asymptomatic. He is
now being treated prophylactically with 1 gram ofpenicillamine daily. We are aware
of no other published instances of identical twins with Wilson's disease but J. M.
Walshe knows of two unpublished cases (personal communication). It is perhaps
surprising that the twins should have been affected to such a different degree. This
must be environmentally determined and most obviously suggests a difference in
dietary copper intake. The boys were brought up together and have never been
apart, including a short period when they were both in the army. Their eating habits
have always been similar, but for aperiod ofat leasteighteen months, A. G. drank a
large amount ofCoca Cola each day. His brother drank relatively little. Each can of
Coca Cola contains 0.1 mg. of copper.6 The average daily intake of dietary copper
is 2-5 mg.7 If A. G. consumed five or six cans of Coca Cola daily (his reported
51
921% .average) this could represent a 10-25 per cent increase in copper intake compared to
his brother and may have been the crucial environmental difference.
It is of note that heterozygote carriers show biochemical changes in the same
direction as affected individuals but usually to a less marked degree.3 This is seen in
Table 1 where A. G.'s parents, who must beheterozygotes, havemildly abnormal or
borderline normal values. The siblings, other than his twin, have at least one mildly
abnormal change and may be heterozygotes. The ranges of biochemical values for
affected individuals and heterozygotes are so wide that they can over-lap and this
sometimes makes it difficult to differentiate between an affected presymptomatic
individual who needs treatment and a carrier who does not.
Walshe suggests that in such cases a liver biopsy should be carried out for
histological examination and copper estimation. However, the latter is difficult with
a small amount of biopsy material and histochemical methods have often been
found to be unreliable.8 It was also our experience with the liver biopsy from Case 2
that several histochemical techniques failed to demonstrate copper despite
characteristic histological changes both by light and electron microscopy.
Treatment is designed to promote themobilization and excretion ofexcess copper
deposited in the tissues. The drug of choice is d-penicillamine, a chelating agent
introduced in 1956.9 The clinical results can be very rewarding provided treatment is
not delayed until neurological damage is irreversible. This is presumably the
situation in our first case, although improvement may sometimes be delayed for a
year or more after the initiation of treatment.3 Toxic reactions to penicillamine are
not uncommon; these include urticaria and other skin rashes, nausea, anorexia,
vomiting, fever, thrombocytopenia with or without leucopenia and a collagen
disease-like reaction. Other less common signs of toxicity are mouth ulceration,
pyridoxine deficiency, skin fragility, nephrotic syndrome, haemolytic anaemia and
Goodpasture's syndrome.
Fortunately a newer drug, triethylene tetramine dihydrochloride (Trien) was
introduced in 196910 and has been shown to be an equally effective chelating agent
although acting in a slightly different way." Certainly in Case 2 the effect of the
preparation in producing copper excretion was excellent (Fig. 3) and recent
authors12.13 report continued effectiveness and safety withlong term administration.
The drug has only recently become commercially available (1978) and has not
been subject to formal toxicity testing. Trien has therefore not yet been approved by
any national committee. However, it remains the only practical alternative drug to
penicillamine in this disease and has proved biochemically and clinically effective in
this case.
SUMMARY
The clinical presentation, investigation and management of two recent cases of
neurological Wilson's disease are described. Various aspects of the disorder are
discussed and the variety of clinical presentation emphasised.
The first case occurred in only one of monozygotic twins and a possible
explanation for this is considered. In the second patient serious side effects resulted
from the use ofpenicillamine, and a new drug triethylene tetramine dihydrochloride
(Trien) was successfully used as an alternative chelating agent.
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